| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 46.38 KB | Adobe PDF |
Orientador(es)
Resumo(s)
This article has been corrected at the request of the authors to include Virginia Sousa as the fourth author as she was erroneously omitted during the submission process. The authors deeply regret that this error was not identified and addressed prior to publication.
Descrição
Palavras-chave
Immune-checkpoint inhibitors Pseudoprogression Immune-related adverse events Lung cancer Differential diagnosis
Contexto Educativo
Citação
Pantarotto M, Barata R, Coelho R, Cavalheiro C, Rolim I, Tonin FS, et al. Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression. Cureus. 2023;15(2):c101.
Editora
Springer Nature